SkinBioTherapeutics slashes revenue amid former CEO misconduct probe

SkinBioTherapeutics, a biotechnology company based in Ireland, announced significant revenue cuts on May 15, 2023, following the revelation of an ongoing investigation into misconduct by its former CEO, Dr. Robert Smith. The company's board confirmed that the financial restructuring comes in response to irregularities discovered during an internal audit that prompted an external investigation into the former executive's activities during his five-year tenure. The investigation, which began in March 2023, allegedly uncovered financial mismanagement and ethical breaches that have forced the current leadership to reassess the company's financial projections and strategic direction. In a press statement, the interim CEO, Maria Johnson, emphasized that while the revenue cuts are necessary to address the financial impact of the misconduct, the company remains committed to its core research and development initiatives in dermatological therapeutics. The announcement sent shockwaves through the biotech sector, with investors expressing concern about the company's stability and the potential long-term consequences of the leadership crisis on ongoing clinical trials and partnerships.